Karyopharm Therapeutics Files 8-K
Ticker: KPTI · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $6.785, $6.7849, $10.00, $30 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
Related Tickers: KPTI
TL;DR
Karyopharm filed a routine 8-K, no major news.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on March 27, 2026, to report other events. The filing does not contain specific financial figures or new material events beyond the reporting requirement.
Why It Matters
This filing indicates Karyopharm Therapeutics Inc. has submitted a standard 'Other Events' report to the SEC, which may not contain significant new information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose new material information that would immediately impact risk.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Filer
- 0001503802-26-000011 (filing_id) — SEC Accession Number
- 2026-03-27 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' as per Item 8.01.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 27, 2026.
What is the CIK number for Karyopharm Therapeutics Inc.?
The CIK number for Karyopharm Therapeutics Inc. is 0001503802.
What is the business address of Karyopharm Therapeutics Inc.?
The business address of Karyopharm Therapeutics Inc. is 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459.
Does this filing contain specific financial figures or material updates?
Based on the provided information, this filing is categorized under 'Other Events' and does not explicitly detail specific financial figures or new material updates.
Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2026-03-27 08:04:27
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
- $6.785 — "Common Stock"), at a purchase price of $6.785 per share and, in lieu of Common Stock,
- $6.7849 — of Common Stock at a purchase price of $6.7849 per pre-funded warrant, and (ii) accomp
- $10.00 — Common Stock with an exercise price of $10.00 per share to the Investor in a private
- $30 m — lted in gross proceeds of approximately $30 million, before placement agent fees and
- $19.8 m — of sales commissions, of approximately $19.8 million, which amount includes the 1,100,
Filing Documents
- kpti-20260327.htm (8-K) — 59KB
- 0001503802-26-000011.txt ( ) — 170KB
- kpti-20260327.xsd (EX-101.SCH) — 30KB
- kpti-20260327_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: March 27, 2026 By: /s/ Michael Mano Michael Mano Executive Vice President, Chief Legal Officer and Secretary